Brenipatide (LY3537031): Dual GIP/GLP-1 Research Guide

Brenipatide (LY3537031) is an investigational long-acting dual GIP/GLP-1 receptor agonist developed by Eli Lilly and Company, now supported by presented human clinical data across several non-obesity indications, alcohol use disorder among them. The molecule engages two class B1 incretin receptors rather than the single GLP-1 receptor targeted by semaglutide.

Definition: A dual GIP/GLP-1 receptor agonist is a single synthetic peptide engineered to activate both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Brenipatide belongs to this co-agonist class, the same mechanistic family as tirzepatide, and carries the Lilly development code LY3537031.

What is brenipatide (LY3537031)?

Brenipatide is a clinical-stage incretin co-agonist peptide, publicly identified by the development code LY3537031 and attributed to Eli Lilly and Company. The program is notable because its disclosed indication set sits outside obesity and type 2 diabetes, the two areas that have absorbed almost all incretin development attention since 2021.

Compound identity data — CAS number, molecular formula and molecular weight — is maintained on the compound reference library, which is the one page on this site that keeps it current.

Chemical identity remains thin in the public record. No peer-reviewed structural paper, registry-assigned CAS number or residue-by-residue sequence for brenipatide has entered general circulation, which means any figure claiming to be its molecular weight should be treated as unsourced until a primary disclosure appears. That gap matters for laboratories that build assays around exact molar concentrations, because a co-agonist of unknown mass cannot be dosed accurately in a cAMP or binding experiment.

In plain terms: the mechanism class is known, the sponsor is known, the chemistry is not yet public.

How does a dual GIP/GLP-1 receptor agonist work at the receptor level?

Dual agonism works by driving cyclic AMP production through two separate incretin receptors with one ligand. Both GIPR and GLP-1R couple primarily to Gαs, so agonist binding raises intracellular cAMP and activates protein kinase A in the target cell, with β-arrestin recruitment and receptor internalization shaping the duration of that signal.

The native hormones are short-lived. Human GIP is a 42-amino-acid peptide; the active circulating form of GLP-1 is the 30-residue GLP-1(7-36)amide. Dipeptidyl peptidase-4 cleaves both near the N-terminus, after Ala⁸ in the case of GLP-1, which collapses native GLP-1 plasma half-life to roughly 1.5 to 2 minutes and native GIP to around 5 to 7 minutes. No unmodified incretin can be used as a once-weekly pharmacological agent for that reason alone.

Engineering around that constraint has followed a consistent path in the published peptide chemistry literature: substitute the DPP-4 recognition residue, stabilize the helical mid-domain, then attach a fatty diacid that binds serum albumin reversibly. Tirzepatide combines those elements and shows a reported elimination half-life near 5 days, which is what makes weekly administration feasible. Brenipatide is described as long-acting, implying a comparable acylation or albumin-binding strategy, though the specific modification has not been published.

Short version: change the protease site, add a lipid anchor, gain days instead of minutes.

Why is a GIP/GLP-1 co-agonist being studied for alcohol use disorder?

The rationale is central, not peripheral. GLP-1 receptors are expressed in hindbrain nucleus tractus solitarius neurons and in mesolimbic structures including the ventral tegmental area and nucleus accumbens, the circuitry that encodes drug and alcohol reinforcement, and receptor agonism in those regions blunts alcohol-motivated behavior in rodents.

Published preclinical work established this well before any incretin entered an addiction trial. Rodent operant self-administration and two-bottle-choice studies using exendin-4 and, later, semaglutide reported reductions in voluntary ethanol intake and in cue-induced reinstatement, with effects that persisted at doses below those producing frank food avoidance. Complementary work implicated accumbal dopamine release as the proximate readout, and lesion or site-specific microinjection designs placed part of the effect inside the ventral tegmental area rather than purely at the level of nausea or malaise.

GIP receptor contribution is the open question. GIPR is expressed in brain regions that overlap incompletely with GLP-1R, and the pharmacological consequence of engaging both receptors in reward circuitry has not been characterized in humans. Whether the GIP arm of a co-agonist adds to, subtracts from, or simply tolerates the GLP-1 arm in this context is unresolved in the published record, and the interpretation of any brenipatide result in alcohol use disorder depends on it.

A reasonable summary of the consensus in the incretin neuroscience literature: receptor distribution in the central nervous system, not peripheral insulinotropic potency, is what predicts behavioral effects on reward.

How does brenipatide compare with tirzepatide?

Both compounds are Lilly-originated dual GIP/GLP-1 receptor agonists, and that shared mechanism class is where the symmetry ends. Tirzepatide has a published structure, an approved label and Phase 3 outcome data; brenipatide has a development code, a stated indication focus and no public chemistry. No head-to-head comparative study of brenipatide and tirzepatide has been published, so the table below sets two unequal evidence bases side by side rather than two comparable datasets.

Read that last set of rows carefully before designing anything around brenipatide. A compound with no published mass and no published sequence cannot be reproduced, verified or independently assayed, which is a practical limit on what any laboratory outside the sponsor can currently do with it. Researchers who need a characterized incretin co-agonist for bench work generally work with reference material whose identity is confirmed by mass spectrometry and whose purity is documented, and our in-depth compound research guides cover the characterized members of this class in detail.

What did the new human data establish, and what did it not?

Company-presented human data on brenipatide moves the compound from a pipeline code into a clinical-stage asset with disclosed indication intent. What a conference presentation does not do is deliver the peer-reviewed methods section, the full randomization scheme or the primary dataset that independent reviewers need.

Three categories are worth separating.

• Established: brenipatide is a Lilly dual GIP/GLP-1 receptor agonist that has been administered to humans, with alcohol use disorder named among its non-obesity targets.
• Contested or incomplete: effect sizes, exposure-response relationships and the relative contribution of GIPR versus GLP-1R engagement to any behavioral readout.
• Unknown: molecular formula, molecular weight, CAS assignment, full sequence, receptor selectivity ratios and central nervous system penetration in humans.

Incretin pharmacology has a track record of early signals that shrank under replication. Rodent ethanol intake reductions were reported consistently across laboratories for GLP-1 receptor agonists, yet translation to controlled human trials in alcohol use disorder has been uneven, and the fair position is that a mechanism supported by convergent animal data is not the same thing as a mechanism demonstrated in people. Treat the brenipatide presentation as the start of a translational argument rather than its conclusion.

How do laboratories characterize an incretin co-agonist in vitro?

Characterization of a dual agonist requires testing each receptor separately before testing them together. The standard sequence used in published receptor pharmacology runs as follows.

1. Reconstitute and verify concentration. Dissolve the lyophilized peptide in a validated vehicle, then confirm concentration by UV absorbance at 280 nm or by quantitative amino acid analysis rather than assuming the vial label.
2. Confirm identity and purity. Run reverse-phase HPLC with mass spectrometric detection; a research-grade sourcing standard for this class is ≥99% by HPLC with a matching observed mass.
3. Assay GLP-1R activity in isolation. Measure cAMP accumulation in a cell line stably expressing human GLP-1R, typically HEK293 or CHO, and fit a full concentration-response curve for EC₅₀ and maximal efficacy.
4. Assay GIPR activity in isolation. Repeat the cAMP protocol in a matched line expressing human GIPR, using native GIP as the reference agonist so that relative potency is interpretable.
5. Quantify biased signaling. Compare β-arrestin recruitment and receptor internalization against cAMP output, since co-agonists in this class differ more in bias and internalization kinetics than in raw potency.
6. Test protease stability. Incubate with recombinant DPP-4 or with plasma, then quantify intact peptide over time to confirm that the N-terminal modification is doing its job.
7. Check species orthology. Repeat key assays at rodent receptors before interpreting any animal experiment, because GIPR shows meaningful sequence divergence between human and rodent.

Skipping step 4 is the most common error. A compound described as a dual agonist can be functionally GLP-1R-dominant at achievable concentrations, and only a matched GIPR curve reveals that.

How should incretin-class research peptides be stored and handled?

Lyophilized incretin peptides are stable for extended periods at −20 °C when kept desiccated and shielded from light, while reconstituted solutions degrade on a scale of days to weeks at 2 to 8 °C. Acylated co-agonists carry an additional risk: the fatty diacid promotes surface adsorption and self-association, so low-concentration working solutions lose material to tube walls.

Practical handling points that show up repeatedly in method sections for this class include aliquoting immediately after reconstitution to avoid repeated freeze-thaw cycles, using low-binding polypropylene rather than glass for dilute stocks, and recording the reconstitution date on every aliquot. Carrier protein at 0.1% BSA is frequently added to dilute working solutions for assay work, though it must be omitted where downstream mass spectrometry would be compromised.

One more point on documentation. Every lot used in a publishable experiment should be traceable to an analytical certificate, and the third-party HPLC results and Certificates of Analysis for a given lot are the record that makes a purity claim checkable rather than assertable.

What should researchers look for in an incretin peptide supplier?

Identity confirmation by mass spectrometry, quantified purity by HPLC and lot-level traceability are the three things that separate usable reference material from an unverifiable vial. A supplier that publishes analytical data per lot lets a laboratory reproduce its own work six months later.

Peptide.Express applies a ≥99% HPLC purity standard as a sourcing requirement across its research peptide catalog, with independent analytical verification documented per lot rather than per product line. That distinction matters: a sourcing standard describes what is accepted into inventory, while a measured figure on a Certificate of Analysis describes one specific batch, and the two should never be quoted interchangeably. Our purity standards and quality assurance process documents how incoming material is screened, and the research peptide catalog lists the characterized compounds currently available for laboratory use.

Brenipatide itself is not available as research reference material, and any vendor claiming to supply it should be asked for the analytical data that would identify it.

Research use disclaimer

All compounds and mechanisms described here are discussed strictly in the context of in-vitro laboratory research and preclinical investigation. Research peptides sold by Peptide.Express are for research use only. They are not drugs, not dietary supplements, and not approved for human or veterinary administration, diagnostic use, or any clinical application. Brenipatide is an investigational agent under sponsor control and is not an approved product in any jurisdiction. Nothing in this guide describes or endorses administration to humans or animals.